Skip to main content
padlock icon - secure page this page is secure

A Novel Methotrexate Delivery System Based on Chitosan-Methotrexate Covalently Conjugated Nanoparticles

Buy Article:

$106.87 + tax (Refund Policy)

In this paper, a chitosan-methotrexate covalently conjugated nanoparticles (CS-MTX-TPP NPs) has been developed as a potential delivery system for methotrexate (MTX). MTX was first conjugated to CS by using glutaraldehyde as cross-linked agent, and followed by the process of ionic gelation between MTX-conjugated CS and sodium tripolyphosphate (TPP) to form CS-MTX-TPP NPs at mild reaction conditions. The hydrodynamic diameter of CS-MTX-TPP NPs and the encapsulation efficiency of MTX were affected by the weight ratio of MTX/CS. At the ratio of 1/11, the mean hydrodynamic diameter of CS-MTX-TPP NPs was the lowest (187.9±9.0 nm) and the nanoparticles presented the encapsulation efficiency of MTX with 53.0±3.2%. The characterizations by atomic force microscopy (AFM) and photon correlation spectroscopy (PCS) showed the CS-MTX-TPP NPs had a spherical shape and good dispersion with diameter of sub-200-nm and zeta potential of 30 mV. Additionally, in vitro release test revealed that the stable covalent bonding of CS and MTX was beneficial for providing slow release for MTX. Especially, cellular toxicity study in MCF-7 cancer cells further demonstrated the effective anticancer efficacy of this new type of delivery for MTX.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: October 1, 2009

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more